查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1790429

美國辦公室實驗室市場規模、佔有率和趨勢分析：按模式、服務、專業和細分市場預測，2025 年至 2033 年

U.S. Office-based Labs Market Size, Share & Trends Analysis Report By Modality (Single Specialty, Multi-Specialty), By Service (Cardiac, Endovascular Intervention, Venous), By Specialist, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

美國辦公室實驗室市場摘要

美國辦公室實驗室市場規模預計在 2024 年將達到 139 億美元，預計到 2033 年將達到估計值億美元，2025 年至 2033 年的複合年成長率為 11.16%。近年來，美國患者對辦公室實驗室的偏好日益增加，以及門診手術介入的趨勢日益增強，是推動市場成長的關鍵因素。辦公室實驗室 (OBL) 在轉變醫療保健提供系統、支援醫療設備、設備和其他產品的成長方面發揮關鍵作用。快速變化的醫療保健提供格局正在推動主要市場參與者轉變經營模式，以從持續轉型中獲得最大收益。

美國心血管和放射科手術數量的不斷成長是門診實驗室 (OBL) 市場成長要素。根據《2024 年心臟病和中風統計報告》，近一半（48.6%）的美國人口患有某種形式的心血管疾病，例如心臟疾病、心臟衰竭、中風或高血壓。日益加重的疾病負擔導致對診斷和介入治療的需求不斷成長，從而促進了市場的成長。

周邊動脈疾病尤其推動了門診介入治療的需求。根據美國心臟協會2022年的報告，周邊動脈疾病(PAD)影響美國約850萬40歲以上的人。周邊動脈疾病通常需要微創血管介入治療，例如血管成形術、切除術和置入術，這些治療擴大在門診進行。

第1章調查方法與範圍

第2章執行摘要

  • 市場概述
  • 市場區隔
  • 市場區隔
  • 競爭格局

第3章市場變數、趨勢和範圍

  • 市場體系展望
    • 母市場展望
    • 補貼市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
    • 市場機會分析
    • 市場問題分析
  • 法規結構和報銷方案
    • 法律規範
    • 贖回情景
  • 商業環境分析工具
    • 波特五力分析
    • PESTLE分析

第4章：美國辦公室實驗室市場：按模式的估計和趨勢分析

  • 2024 年及 2033 年美國辦公室實驗室市場趨勢及佔有率分析（按模式）
  • 美國辦公室實驗室市場細分儀表板（按模式）
  • 美國辦公室實驗室市場規模及預測（按模式）
    • 單一專業實驗室
    • 多專業實驗室
    • 混合實驗室

第5章：美國辦公室實驗室市場：按服務進行的估算和趨勢分析

  • 2024 年及 2033 年美國辦公室實驗室市場趨勢及服務佔有率分析
  • 美國辦公室實驗室市場細分儀表板：按服務
  • 美國辦公室實驗室市場規模及服務預測
    • 周邊血管介入治療
    • 心
    • 介入放射學
    • 靜脈
    • 血管內介入治療
    • 其他

第6章：美國辦公室實驗室市場：專業估算與趨勢分析

  • 2024 年及 2033 年美國辦公室實驗室市場趨勢及專業佔有率分析
  • 美國辦公室實驗室市場細分儀表板（按專業分類）
  • 美國辦公室實驗室市場規模及專業預測
    • 血管外科醫師
    • 介入性心臟病學
    • 介入放射學
    • 其他

第7章美國辦公室實驗室市場：競爭格局

  • 供應商競爭分類
  • 服務供應商競爭分類
  • 戰略地圖
  • 公司簡介
Product Code: 2-68038-900-5

U.S. Office-based Labs Market Summary

The U.S. office-based labs market size was estimated at USD 13.90 billion in 2024 and is expected to reach an estimated value of USD 35.21 billion by 2033, growing at a CAGR of 11.16% from 2025 to 2033. Growing preference for office-based labs by patients in the U.S. in recent years and the increasing trend of performing surgical interventions in outpatient settings are among key factors driving the market growth. Office-based labs (OBLs) are playing a vital role in transforming the healthcare delivery system and are supporting the growth of medical devices, equipment, and other products.The rapidly transitioning healthcare delivery scenario is driving key market players to transform their business models to achieve maximum benefit from ongoing transition.

The rising number of cardiovascular and radiological procedures in the U.S. is a significant growth driver for the office-based labs (OBLs) market. Cardiovascular disease remains the leading cause of death in the U.S. A report from the 2024 Heart Disease and Stroke Statistics indicates that nearly half of the U.S. population (48.6%) has some form of cardiovascular disease, including coronary heart disease, heart failure, stroke, and high blood pressure. This growing disease burden is translating into an increased demand for diagnostic and interventional procedures, thereby supplementing market growth.

Peripheral artery disease in particular is fueling demand for outpatient interventional care. According to the American Heart Association report published in 2022, peripheral artery disease (PAD) affected approximately 8.5 million people aged 40 and in the U.S. Peripheral artery disease often requires minimally invasive vascular interventions, such as angioplasty, atherectomy, or stenting, which are increasingly being performed in outpatient settings.

U.S. Office-based Labs Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. office-based labs market report based on service, modality, and specialist:

  • Services Outlook (Revenue, USD Million, 2021 - 2033)
  • Peripheral Vascular Intervention
    • Atherectomy
    • Vascular Angioplasty
    • Stenting
    • Other PVI
  • Endovascular Interventions
  • Cardiac
  • Interventional radiology
    • Uterine Fibroid Embolization (UFE)
    • Prostate Artery Embolization (PAE)
    • Y90/Oncology
    • Other IR
  • Venous
    • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
    • Sclerotherapy/Glue
    • Venous Stenting
    • Other Deep Vein
  • Others
  • Services Outlook (Number of Procedures, 2021 - 2033)
  • Peripheral Vascular Intervention
    • Atherectomy
    • Vascular Angioplasty
    • Stenting
    • Other PVI
  • Endovascular Interventions
  • Cardiac
  • Interventional radiology
    • Uterine Fibroid Embolization (UFE)
    • Prostate Artery Embolization (PAE)
    • Y90/Oncology
    • Other IR
  • Venous
    • RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy)
    • Sclerotherapy/Glue
    • Venous Stenting
    • Other Deep Vein
  • Others
  • Modality Outlook (Revenue, USD Million, 2021 - 2033)
  • Single Specialty
  • Multi-Specialty
  • Hybrid
  • Specialist Outlook (Revenue, USD Million, 2021 - 2033)
  • Vascular Surgeons
  • Interventional Cardiologists
  • Interventional Radiologists
  • Others

Chapter 01 Methodology And Scope

  • 1.1 Market Segmentation & Scope
  • 1.2 Segment Definitions
    • 1.2.1 Estimates And Forecast Timeline
  • 1.3 Research Methodology
    • 1.3.1 Information Procurement
      • 1.3.1.1 Purchased Database
    • 1.3.2 Gvr's Internal Database
      • 1.3.2.1 Secondary Sources
      • 1.3.2.2 Primary Research
  • 1.4 Information Or Data Analysis
    • 1.4.1 Data Analysis Models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Three Pillars Of Market Estimation
      • 1.6.1.1 Secondary Market Research
      • 1.6.1.2 Primary Market Intelligence
        • 1.6.1.2.1. In-Depth Interviews (Idis)
        • 1.6.1.2.2. Online Survey Program
    • 1.6.2 Market Modeling & Forecasting
      • 1.6.2.1 Procedure Volume Estimation (2021-2024)
      • 1.6.2.2 Average Cost Estimation (2021-2024)
      • 1.6.2.3 Forecasting (2025-2033)
      • 1.6.2.4 Segment Share Analysis
  • 1.7 List Of Secondary Sources
  • 1.8 List Of Abbreviations
  • 1.9 Objectives
    • 1.9.1 Objective - 1
    • 1.9.2 Objective - 2
    • 1.9.3 Objective - 3

Chapter 02 Executive Summary

  • 2.1 Market Snapshot
  • 2.2 Market Segmentation
  • 2.3 Market Segmentation
  • 2.4 Competitive Landscape

Chapter 03 Market Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 Parent Market Outlook
    • 3.1.2 Ancillary Market Outlook
  • 3.2 Market Dynamics
    • 3.2.1 Market Driver Analysis
      • 3.2.1.1 Increasing Volume Of Cardiovascular And Radiological Procedures
        • 3.2.1.1.1. Case Study: Peripheral Vascular Interventions For Peripheral Artery Disease (Pad) In Office-Based Labs
      • 3.2.1.2 Growing Preference For Office-Based Labs Over Hospitals
        • 3.2.1.2.1. Case Study: Trends In Peripheral Vascular Interventions And The Rise Of Office-Based Laboratories In The U.S.
        • 3.2.1.2.2. Case Study: Utilization Patterns And Outcomes Of Pad Procedures In Office-Based Labs Versus Hospitals.
      • 3.2.1.3 Advancing Technology And Rising Preference For Minimally Invasive Procedures
    • 3.2.2 Market Restraint Analysis
      • 3.2.2.1 High Risk Option For Severe Cases
      • 3.2.2.2 High Capital Investment And Operational Costs
    • 3.2.3 Market Opportunity Analysis
      • 3.2.3.1 Strategic Partnerships And Physician Ownership
    • 3.2.4 Market Challenges Analysis
      • 3.2.4.1 Competitive Pressure From Ambulatory Surgical Centers (Ascs) And Hospital Outpatient Departments (Hopds)
  • 3.3 Regulatory Framework & Reimbursement Scenario
    • 3.3.1 Regulatory Framework
    • 3.3.2 Reimbursement Scenario
  • 3.4 Business Environment Analysis Tools
    • 3.4.1 Porter's Five Forces Analysis
    • 3.4.2 Pestle Analysis

Chapter 04 U.S. Office-Based Labs Market: Modality Estimates & Trend Analysis

  • 4.1 U.S. Office-Based Labs Market: Modality Movement Share Analysis, 2024 & 2033
  • 4.2 U.S. Office-Based Labs Market: Modality Segment Dashboard
  • 4.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Modality (Usd Billion)
    • 4.3.1 Single Specialty Labs
      • 4.3.1.1 Single Specialty Labs Market, 2021 - 2033 (Usd Billion)
    • 4.3.2 Multi-Specialty Labs
      • 4.3.2.1 Multi-Specialty Labs Market, 2021 - 2033 (Usd Billion)
    • 4.3.3 Hybrid Labs
      • 4.3.3.1 Hybrid Labs Market, 2021 - 2033 (Usd Billion)

Chapter 05 U.S. Office-Based Labs Market: Service Estimates & Trend Analysis

  • 5.1 U.S. Office-Based Labs Market: Service Movement Share Analysis, 2024 & 2033
  • 5.2 U.S. Office-Based Labs Market: Service Segment Dashboard
  • 5.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Service (Usd Billion)
    • 5.3.1 Peripheral Vascular Intervention
      • 5.3.1.1 Reimbursement Scenario
      • 5.3.1.2 Peripheral Vascular Intervention Market, 2021 - 2033 (Usd Billion)
      • 5.3.1.3 Peripheral Vascular Intervention Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.4 Atherectomy
        • 5.3.1.4.1 Atherectomy Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.4.2 Atherectomy Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.5 Vascular Angioplasty
        • 5.3.1.5.1 Vascular Angioplasty Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.5.2 Vascular Angioplasty Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.6 Stenting
        • 5.3.1.6.1 Stenting Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.6.2 Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.1.7 Other Pvi
        • 5.3.1.7.1 Other Pvi Market, 2021 - 2033 (Usd Billion)
        • 5.3.1.7.2 Other Pvi Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.2 Cardiac
      • 5.3.2.1 Reimbursement Scenario
      • 5.3.2.2 Cardiac Market, 2021 - 2033 (Usd Billion)
      • 5.3.2.3 Cardiac Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.3 Interventional Radiology
      • 5.3.3.1 Reimbursement Scenario
      • 5.3.3.2 Interventional Radiology Market, 2021 - 2033 (Usd Billion)
      • 5.3.3.3 Interventional Radiology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.4 Uterine Fibroid Embolization (Ufe)
        • 5.3.3.4.1 Uterine Fibroid Embolization (Ufe) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.4.2 Uterine Fibroid Embolization (Ufe) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.5 Prostate Artery Embolization (Pae)
        • 5.3.3.5.1 Prostate Artery Embolization (Pae) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.5.2 Prostate Artery Embolization (Pae) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.6 Y90/Oncology
        • 5.3.3.6.1 Y90/Oncology Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.6.2 Y90/Oncology Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.7 Other Ir
        • 5.3.3.7.1 Other Ir Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.7.2 Other Ir Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.4 Venous
      • 5.3.4.1 Reimbursement Scenario
      • 5.3.4.2 Venous Market, 2021 - 2033 (Usd Million)
      • 5.3.4.3 Venous Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.4 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy)
        • 5.3.3.4.1 Rfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.4.2 Urfa (Radiofrequency Ablation) And Evlt (Endovenous Laser Therapy) Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.5 Sclerotherapy/Glue
        • 5.3.3.5.1 Sclerotherapy/Glue Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.5.2 Sclerotherapy/Glue Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.6 Venous Stenting
        • 5.3.3.6.1 Venous Stenting Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.6.2 Venous Stenting Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
      • 5.3.3.7 Other Deep Vein
        • 5.3.3.7.1 Other Deep Vein Market, 2021 - 2033 (Usd Billion)
        • 5.3.3.7.2 Other Deep Vein Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.5 Endovascular Interventions
      • 5.3.5.1 Reimbursement Scenario
      • 5.3.5.2 Endovascular Interventions Market, 2021 - 2033 (Usd Million)
      • 5.3.5.3 Endovascular Interventions Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)
    • 5.3.6 Others
      • 5.3.6.1 Reimbursement Scenario
      • 5.3.6.2 Other Services Market, 2021 - 2033 (Usd Million)
      • 5.3.6.3 Other Services Procedure Volume Estimates & Forecasts, 2021 - 2033 (Units)

Chapter 06 U.S. Office-Based Labs Market: Specialist Estimates & Trend Analysis

  • 6.1 U.S. Office-Based Labs Market: Specialist Movement Share Analysis, 2024 & 2033
  • 6.2 U.S. Office-Based Labs Market: Specialist Segment Dashboard
  • 6.3 U.S. Office-Based Labs Market Size & Forecast And Forecasts, By Specialist (Usd Billion)
    • 6.3.1 Vascular Surgeons
      • 6.3.1.1 Vascular Surgeons Market, 2021 - 2033 (Usd Billion)
    • 6.3.2 Interventional Cardiologists
      • 6.3.2.1 Interventional Cardiologists Market, 2021 - 2033 (Usd Billion)
    • 6.3.3 Interventional Radiologists
      • 6.3.3.1 Interventional Radiologists Market, 2021 - 2033 (Usd Billion)
    • 6.3.4 Other Specialists
      • 6.3.4.1 Other Specialists Market, 2021 - 2033 (Usd Billion)

Chapter 07 U.S. Office-Based Labs Market: Competitive Landscape

  • 7.1 Suppliers' Competition Categorization
  • 7.2 Service Providers' Competition Categorization
    • 7.2.1 Company Market Position Analysis: Suppliers
    • 7.2.2 Company Market Position Analysis: Service Provider
  • 7.3 Strategy Mapping
    • 7.3.1 New Launch And Approval
    • 7.3.2 Acquisition
    • 7.3.3 Partnership & Collaboration
    • 7.3.4 Others
  • 7.4 Company Profiles
    • 7.3.1 Koninklijke Philips N.V.
      • 7.3.1.1 Company Overview
      • 7.3.1.2 Financial Performance
      • 7.3.1.3 Product/Service Benchmarking
      • 7.3.1.4 Strategic Initiatives
    • 7.3.2 Ge Healthcare
      • 7.3.2.1 Company Overview
      • 7.3.2.2 Financial Performance
      • 7.3.2.3 Product/Service Benchmarking
      • 7.3.2.4 Strategic Initiatives
    • 7.3.3 Siemens Healthineers Ag
      • 7.3.3.1 Company Overview
      • 7.3.3.2 Financial Performance
      • 7.3.3.3 Product/Service Benchmarking
      • 7.3.3.4 Strategic Initiatives
    • 7.3.4 Medtronic Plc
      • 7.3.4.1 Company Overview
      • 7.3.4.2 Financial Performance
      • 7.3.4.3 Product/Service Benchmarking
      • 7.3.4.4 Strategic Initiatives
    • 7.3.5 Boston Scientific Corporation
      • 7.3.5.1 Company Overview
      • 7.3.5.2 Financial Performance
      • 7.3.5.3 Product/Service Benchmarking
      • 7.3.5.4 Strategic Initiatives
    • 7.3.6 Abbott
      • 7.3.6.1 Company Overview
      • 7.3.6.2 Financial Performance
      • 7.3.6.3 Product/Service Benchmarking
      • 7.3.6.4 Strategic Initiatives
    • 7.3.7 Envision Healthcare Corporation (Kkr)
      • 7.3.7.1 Company Overview
      • 7.3.7.2 Financial Performance
      • 7.3.7.3 Product/Service Benchmarking
      • 7.3.7.4 Strategic Initiatives
    • 7.3.8 Surgical Care Affiliates (Sca)
      • 7.3.8.1 Company Overview
      • 7.3.8.2 Financial Performance
      • 7.3.8.3 Product/Service Benchmarking
      • 7.3.8.4 Strategic Initiatives
    • 7.3.9 Surgery Partners
      • 7.3.9.1 Company Overview
      • 7.3.9.2 Financial Performance
      • 7.3.9.3 Product/Service Benchmarking
      • 7.3.9.4 Strategic Initiatives
    • 7.3.10 Cardiovascular Coalition
      • 7.3.10.1 Company Overview
      • 7.3.10.2 Financial Performance
      • 7.3.10.3 Product/Service Benchmarking
      • 7.3.10.4 Strategic Initiatives
    • 7.3.11 Th Medical
      • 7.3.11.1 Company Overview
      • 7.3.11.2 Financial Performance
      • 7.3.11.3 Product/Service Benchmarking
      • 7.3.11.4 Strategic Initiatives
    • 7.3.12 Vascular Care Group
      • 7.3.12.1 Company Overview
      • 7.3.12.2 Financial Performance
      • 7.3.12.3 Product/Service Benchmarking
      • 7.3.12.4 Strategic Initiatives
    • 7.3.13 Coastal Vascular Institute
      • 7.3.13.1 Company Overview
      • 7.3.13.2 Financial Performance
      • 7.3.13.3 Product/Service Benchmarking
      • 7.3.14.4 Strategic Initiatives

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of abbreviations
  • Table 3 Type of procedures performed in OBLs
  • Table 4 Catheter Placement(s): Medicare base case coding scenarios
  • Table 5 Arterial Shunting Coil Embolization (if required): Medicare base case coding scenarios
  • Table 6 Hepatic Angiogram: Medicare base case coding scenarios
  • Table 7 Volume Imaging Options: Medicare base case coding scenarios
  • Table 8 CT Acquisition (maybe billed in conjunction with CPT 76377): Medicare base case coding scenarios
  • Table 9 Mapping Options: Medicare base case coding scenarios
  • Table 10 Codes applicable between mapping and treatment: Medicare base case coding scenarios
  • Table 11 Catheter Placement (Phase II): Medicare base case coding scenarios
  • Table 12 Hepatic Angiogram (Phase II): Medicare base case coding scenarios
  • Table 13 Tumor Embolization Phase II: Medicare base case coding scenarios
  • Table 14 Microspheres Administration: Authorized User Codes (AU)
  • Table 15 Post Treatment Imaging (Provider Preference): Medicare base case coding scenarios
  • Table 16 U.S. office-based labs market revenue estimates and forecast, by Modality, 2021 - 2033 (USD billion)
  • Table 17 U.S. office-based labs market revenue estimates and forecast, by Service, 2021 - 2033 (USD billion)
  • Table 18 U.S. office-based labs market revenue estimates and forecast, by Service, 2021 - 2033 (Number of Procedures)
  • Table 19 U.S. Peripheral Vascular Intervention (PVI) in OBLs market revenue estimates and forecast, by Service, 2021 - 2033 (USD Million)
  • Table 20 U.S. Peripheral Vascular Intervention (PVI) in OBLs market revenue estimates and forecast, by Service Type, 2021 - 2033 (Number of Procedures)
  • Table 21 U.S. venous procedures in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (USD Million)
  • Table 22 U.S. venous procedures in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (Number of Procedures)
  • Table 23 U.S. interventional radiology in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (USD Million)
  • Table 24 U.S. interventional radiology in OBLs market revenue estimates and forecast, by service type, 2021 - 2033 (Number of Procedures)
  • Table 25 U.S. office-based labs market revenue estimates and forecast, by Specialist, 2021 - 2033 (USD billion)
  • Table 26 Shortage of vascular surgeons by workload analysis

List of Figures

  • Fig. 1 U.S. office-based labs segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modeling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Research methodology framework
  • Fig. 10 Secondary research framework
  • Fig. 11 Secondary research framework
  • Fig. 12 Market snapshot
  • Fig. 13 Market segmentation
  • Fig. 14 Market segmentation
  • Fig. 15 Competitive landscape
  • Fig. 16 U.S. office-based labs market dynamics
  • Fig. 17 U.S. office-based labs market: Porter's five forces analysis
  • Fig. 18 U.S. office-based labs market: PESTLE analysis
  • Fig. 19 U.S. office-based labs market: Modality movement share analysis
  • Fig. 20 U.S. office-based labs market: Modality segment dashboard
  • Fig. 21 Single specialty labs market, 2021 - 2033 (USD Billion)
  • Fig. 22 Multi-specialty labs market, 2021 - 2033 (USD Billion)
  • Fig. 23 Hybrid market, 2021 - 2033 (USD Billion)
  • Fig. 24 U.S. office-based labs market: Service movement share analysis
  • Fig. 25 U.S. office-based labs market: Service segment dashboard
  • Fig. 26 Peripheral vascular intervention market, 2021 - 2033 (USD Billion)
  • Fig. 27 Peripheral vascular intervention procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 28 Atherectomy market, 2021 - 2033 (USD Billion)
  • Fig. 29 Atherectomy procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 30 Vascular angioplasty market, 2021 - 2033 (USD Billion)
  • Fig. 31 Vascular angioplasty procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 32 Stenting market, 2021 - 2033 (USD Billion)
  • Fig. 33 Stenting procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 34 Other PVI market, 2021 - 2033 (USD Billion)
  • Fig. 35 Other PVI procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 36 Cardiac market, 2021 - 2033 (USD Billion)
  • Fig. 37 Cardiac procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 38 Interventional radiology market, 2021 - 2033 (USD Billion)
  • Fig. 39 Interventional radiology procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 40 Uterine Fibroid Embolization (UFE) market, 2021 - 2033 (USD Billion)
  • Fig. 41 Uterine Fibroid Embolization (UFE) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 42 Prostate Artery Embolization (PAE) market, 2021 - 2033 (USD Billion)
  • Fig. 43 Prostate Artery Embolization (PAE) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 44 Y90/Oncology market, 2021 - 2033 (USD Billion)
  • Fig. 45 Y90/Oncology procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 46 Other IR market, 2021 - 2033 (USD Billion)
  • Fig. 47 Other IR procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 48 Venous market, 2021 - 2033 (USD Million)
  • Fig. 49 Venous procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 50 RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy) market, 2021 - 2033 (USD Million)
  • Fig. 51 RFA (Radiofrequency Ablation) and EVLT (Endovenous Laser Therapy) procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 52 Sclerotherapy/Glue market, 2021 - 2033 (USD Million)
  • Fig. 53 Sclerotherapy/Glue procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 54 Venous stenting market, 2021 - 2033 (USD Million)
  • Fig. 55 Venous stenting procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 56 Other deep vein market, 2021 - 2033 (USD Million)
  • Fig. 57 Other deep vein procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 58 Endovascular interventions market, 2021 - 2033 (USD Million)
  • Fig. 59 Endovascular interventions procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 60 Other services market, 2021 - 2033 (USD Million)
  • Fig. 61 Other services procedure volume estimates & forecasts, 2021 - 2033 (Units)
  • Fig. 62 U.S. office-based labs market: Specialist movement share analysis
  • Fig. 63 U.S. office-based labs market: Specialist segment dashboard
  • Fig. 64 Vascular surgeons market, 2021 - 2033 (USD Billion)
  • Fig. 65 Interventional cardiologists market, 2021 - 2033 (USD Billion)
  • Fig. 66 Interventional radiologists market, 2021 - 2033 (USD Billion)
  • Fig. 67 Other specialists market, 2021 - 2033 (USD Billion)
  • Fig. 68 Suppliers' competition categorization
  • Fig. 69 Service providers' competition categorization
  • Fig. 70 Company market position analysis: Suppliers
  • Fig. 71 Company market position analysis: Service providers
  • Fig. 72 Strategy mapping